Evotec SE (EVO) Stock

Evotec SE serves as a key partner in drug discovery and development within the global pharmaceutical and biotechnology sectors. Specializing in various therapeutic areas including diabetes, fibrosis, infectious diseases, CNS disorders, oncology, pain management, immunology, rare diseases, respiratory ailments, and women's health, Evotec is dedicated to advancing pharmaceutical products that address critical medical needs.

The company collaborates extenssively with industry leaders such as Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd., Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. These partnerships leverage Evotec's expertise in drug discovery technologies and platforms to accelerate the development of innovative therapies and treatments.

Established in 1993 and headquartered in Hamburg, Germany, Evotec SE was formerly known as Evotec AG before rebranding in April 2019. The company's strategic location and global presence enable it to maintain a robust portfolio of collaborations and initiatives aimed at advancing therapeutic breakthroughs and improving patient outcomes worldwide.